Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Information

Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

	Year Ended
	December 31,
	2025		2024
Program expenses related to clinical-stage product candidates	$	(19,454,384)	$	(13,817,021)
Program expenses related to preclinical and discovery programs		(504,013)		(884,049)
Program expenses related to clinical manufacturing candidates		(2,493,101)		(2,589,833)
Personnel-related expenses (including stock-based compensation)		(4,857,879)		(6,560,070)
General and administrative professional and consultant fees		(1,649,327)		(1,667,063)
Other segment items1		(736,554)		(1,176,892)
Interest income		699,061		331,849
Other non-cash income (expense) items2		142,000		1,772,704
Net Loss	$	(28,854,197)	$	(24,590,375)

¹ Other segment items included in net loss include insurance expense, rent expense, information technology expenses, listing/printing fees, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items include financing costs from our ELOC and change in fair value of our liability classified warrants.